{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:03:27Z","timestamp":1781816607688,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.imbio.2025.153107","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:25:29Z","timestamp":1755037529000},"page":"153107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Proportional and functional anomalies of CD38+ NK Cells:A new mechanism for impaired anti-tumour immunity in multiple myeloma?"],"prefix":"10.1016","volume":"230","author":[{"given":"Huixian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2025.153107_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","article-title":"Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities","volume":"13","author":"Bisht","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.imbio.2025.153107_bb0015","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.2023023529","article-title":"NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma","volume":"144","author":"Blanquart","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41420-023-01765-8","article-title":"What happens to regulatory T cells in multiple myeloma","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin. Oncol."},{"issue":"11","key":"10.1016\/j.imbio.2025.153107_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the Total Therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.imbio.2025.153107_bb0035","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.imbio.2025.153107_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.imbio.2025.153107_bb0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.imbio.2025.153107_bb0050","doi-asserted-by":"crossref","unstructured":"Ho C. et al Immune cell differences between patients in different stages of monoclonal plasma cell disorders J. Clin. Oncol. 40 16_suppl 8065 8065.","DOI":"10.1200\/JCO.2022.40.16_suppl.8065"},{"issue":"5","key":"10.1016\/j.imbio.2025.153107_bb0055","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00259-024-07036-7","article-title":"CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies","volume":"52","author":"Huang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"3","key":"10.1016\/j.imbio.2025.153107_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/imm.12921","article-title":"Natural killer cell cytotoxicity and its regulation by inhibitory receptors","volume":"154","author":"Kumar","year":"2018","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.imbio.2025.153107_bb0065","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.imbio.2025.153107_bb0070","first-page":"31","article-title":"Identification of a Prognostic Model based on NK Cell-Related Genes in Multiple Myeloma using Single-Cell and Transcriptomic Data Analysis","volume":"14","author":"Mei","year":"2024","journal-title":"Blood Lymphat Cancer"},{"issue":"3","key":"10.1016\/j.imbio.2025.153107_bb0075","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4049\/jimmunol.1500591","article-title":"CD56brightCD16- NK Cells produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation","volume":"195","author":"Morandi","year":"2015","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.imbio.2025.153107_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121527","article-title":"CD38, a Receptor with Multifunctional Activities: from Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.imbio.2025.153107_bb0090","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2025.153107_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/20406207251314289","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis","volume":"16","author":"Osama","year":"2025","journal-title":"Ther. Adv. Hematol."},{"issue":"10","key":"10.1016\/j.imbio.2025.153107_bb0100","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.imbio.2025.153107_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2025.153107_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.946871","article-title":"CD38(+)CD39(+) NK cells associate with HIV disease progression and negatively regulate T cell proliferation","volume":"13","author":"Qian","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.imbio.2025.153107_bb0120","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/eji.202049028","article-title":"Human NK cells, their receptors and function","volume":"51","author":"Quatrini","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.imbio.2025.153107_bb0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2007.06.009","article-title":"Tumor immunoediting and immunosculpting pathways to cancer progression","volume":"17","author":"Reiman","year":"2007","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.imbio.2025.153107_bb0130","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201658RR","article-title":"GSK-3\u03b2\/\u03b2-catenin pathway plays crucial roles in the regulation of NK cell cytotoxicity against myeloma cells","volume":"37","author":"Ren","year":"2023","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.imbio.2025.153107_bb0135","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1083\/jcb.201712085","article-title":"Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells","volume":"217","author":"Srpan","year":"2018","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.imbio.2025.153107_bb0145","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","article-title":"A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo","volume":"107","author":"von Strandmann","year":"2006","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.imbio.2025.153107_bb0150","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imbio.2025.153107_bb0155","first-page":"1","article-title":"T-cell immune imbalance in rheumatoid arthritis is associated with alterations in NK cells and NK-like T cells expressing CD38","author":"Wang","year":"2021","journal-title":"J. Innate Immun."},{"issue":"1","key":"10.1016\/j.imbio.2025.153107_bb0160","doi-asserted-by":"crossref","first-page":"28702","DOI":"10.1038\/s41598-024-79008-8","article-title":"CD38 modulates cytokine secretion by NK cells through the Sirt1\/NF-\u03baB pathway, suppressing immune surveillance in colorectal cancer","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.imbio.2025.153107_bb0165","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"12","key":"10.1016\/j.imbio.2025.153107_bb0170","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298525002414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298525002414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:01:58Z","timestamp":1762261318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298525002414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0171298525002414"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2025.153107","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proportional and functional anomalies of CD38+ NK Cells:A new mechanism for impaired anti-tumour immunity in multiple myeloma?","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2025.153107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"153107"}}